Communication of biomarker, genetic, lifestyle risk factor profiles for RA
Communication of biomarker, genetic, lifestyle risk factor profiles for RA
批准号:
8293776
负责人:
ELIZABETH W KARLSON
金额:
$39.75万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2017-06-30
关键词:
AdoptedAdoptionAir PollutionAllelesAttitudeAutoantibodiesBehaviorBehavioralBiological MarkersBreast Cancer Risk Assessment ToolClinical ResearchClinical TrialsCommunicationCommunication ToolsComprehensionCounselingDevelopmentDiagnosisDietDietary FactorsDiseaseEarly treatmentEducationEnvironmental Risk FactorEvolutionExogenous Hormone TherapyExposure toFirst Degree RelativeGeneral PopulationGeneticGenetic RiskGenetic screening methodHealth behaviorHealth behavior changeHealth educationHeart DiseasesHospitalsIndividualKnowledgeLife StyleMethodsModelingModificationNational Institute of Arthritis and Musculoskeletal and Skin DiseasesOral healthPamphletsPathogenesisPatientsPeriodontitisPersonal CommunicationPersonsPharmaceutical PreparationsPhasePopulationPredispositionPreventionPreventivePrintingRandomized Controlled TrialsReadabilityReadinessResearchRheumatoid ArthritisRiskRisk BehaviorsRisk FactorsSerumSilicon DioxideSmokingStagingSurveysTestingWomanarmbehavior changebehavior measurementcigarette smokingcomparison groupcytokinedisabilitygene environment interactiongenetic risk factorgenetic varianthigh riskinnovationlifestyle factorsliteracymalignant breast neoplasmmodifiable riskmultidisciplinarypost interventionpre-clinicalpreventrandomized trialwillingness
中文摘要
在类风湿关节炎(RA)诊断前多年在血清中发现自身抗体和细胞因子提示在临床前阶段预防疾病的机会。最近的研究表明,在暴露于环境因素(包括吸烟、牙周炎和饮食因素)后,具有遗传风险因素的个体会发展为类风湿性关节炎。与一般人群相比,一级亲属(FDR)患有类风湿性关节炎的风险增加3- 9倍。尽管对类风湿关节炎发展中的个体危险因素的认识不断扩大,但目前还没有关于如何最好地传达特定个体的生物标志物、遗传和生活方式风险概况以实现类风湿关节炎个性化预防的研究。鉴于最近出现了有效的早期治疗和预防性治疗的前景,类风湿性关节炎的风险预测现在有可能避免高危患者数十年的残疾。在这个项目中,我们将以我们之前的发现和风险模型为基础,开发一个结合生物标志物、遗传和生活方式因素的在线类风湿性关节炎风险计算器。然后,我们将在有症状的类风湿性关节炎患者的一级亲属中使用该风险计算器进行随机对照试验,以测试风险教育和咨询对采取预防性健康行为的准备程度的影响。我们提出以下具体目标:1)开发一个在线RA风险计算器,这是一个包括生物标志物,遗传和生活方式RA风险因素的个性化沟通工具;2)进行一项随机试验,向RA患者的一级亲属传播风险因素概况,以测试使用风险预测概况和教育是否会导致采取行为的准备改变,以降低RA风险和健康行为的改变。我们将进行一项三组随机试验,分配222名fdr接受:(i)印刷的小册子,(ii)在线风险沟通,或(iii)在线风险沟通加健康教育和咨询。我们将在干预后6周,6个月和12个月对这些组进行随访,以确定行为准备的变化,以改变吸烟,口腔健康或饮食行为和健康行为的变化。
英文摘要
The identification of autoantibodies and cytokines in the serum many years prior to the diagnosis of rheumatoid arthritis (RA) suggests opportunities to prevent disease during the pre-clinical phase. Recent research has led to the recognition that RA develops in individuals with genetic risk factors after exposure to environmental factors, including cigarette smoking, periodontitis, and dietary factors. Having a first degree relative (FDR) with RA increases RA risk 3- to 9-fold compared to that in the general population. Despite the expanding knowledge of individual risk factors in the development of RA, there have been no studies of how best to communicate biomarker, genetic and lifestyle risk profiles for a given individual to enable personalized prevention of RA. Given the recent emergence of effective early treatment and the promise of preventive therapies, RA risk prediction now has the potential to avert decades of disability in at-risk patients. In this project, we will build upon our prior discoveries and risk models to develop an online RA risk calculator that combines biomarker, genetic and lifestyle factors. We will then conduct a randomized, controlled trial using this risk calculator in aymptomatic first degree relatives of RA patients in order to test the impact of risk education and counseling upon the readiness to adopt preventive health behaviors. We propose the following specific aims: 1) To develop an online RA risk calculator, a personalized communication tool that includes biomarker, genetic and lifestyle RA risk factors and 2) To conduct a randomized trial of communication of risk factor profiles to first degree relatives of RA patients to test whether use of risk prediction profiles and education will result in change in readiness to undertake behaviors to decrease their RA risk and health behavior change. We will conduct a 3-arm randomized trial, assigning 222 FDRs to receive: (i) a printed pamphlet, (ii) online risk communication or (iii) online risk communication plus health education and counseling. We will follow these groups at 6 weeks, 6 months and 12 months post intervention in order to determine change in behavioral readiness to modify smoking, oral health, or diet behaviors and health behavior change.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
eMERGE Phase IV Clinical Center at Partners HealthCare
-
批准号:10230561
-
项目类别:
-
资助金额:$88.31万
-
财政年份:2020
-
负责人:ELIZABETH W KARLSON
-
依托单位:
Joint Biology Consortium Resource-based Center
-
批准号:10281356
-
项目类别:
-
资助金额:$93.33万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
Human Biosamples Core
-
批准号:10281358
-
项目类别:
-
资助金额:$35.97万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
Joint Biology Consortium Resource-based Center
-
批准号:10454986
-
项目类别:
-
资助金额:$89.32万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
A New England Enrollment Center for PMI Cohort Program
-
批准号:9453746
-
项目类别:
-
资助金额:$342.09万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
A New England Enrollment Center for PMI Cohort Program
-
批准号:9355397
-
项目类别:
-
资助金额:$121.12万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
Human Biosamples Core
-
批准号:10684883
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
Human Biosamples Core
-
批准号:10454988
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2016
-
负责人:ELIZABETH W KARLSON
-
依托单位:
EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE
-
批准号:9493516
-
项目类别:
-
资助金额:$95.32万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
eMERGE Phase IV Clinical Center at Mass General Brigham
-
批准号:10625354
-
项目类别:
-
资助金额:$116.7万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE
-
批准号:8968123
-
项目类别:
-
资助金额:$97.24万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE
-
批准号:9284512
-
项目类别:
-
资助金额:$91.62万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
eMERGE Phase IV Clinical Center at Mass General Brigham
-
批准号:10834530
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE
-
批准号:9134764
-
项目类别:
-
资助金额:$95.32万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
Finding Genomic Profiles of COVID-19 Phenotypes from the EHR
-
批准号:10166411
-
项目类别:
-
资助金额:$40.19万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE
-
批准号:9477855
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
eMERGE Phase IV Clinical Center at Mass General Brigham
-
批准号:10207715
-
项目类别:
-
资助金额:$141.56万
-
财政年份:2015
-
负责人:ELIZABETH W KARLSON
-
依托单位:
ACR Clinical Research Conference
-
批准号:8006327
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:ELIZABETH W KARLSON
-
依托单位:
ACR Clinical Research Conference
-
批准号:8207806
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:ELIZABETH W KARLSON
-
依托单位:
ACR Clinical Research Conference
-
批准号:8315729
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:ELIZABETH W KARLSON
-
依托单位:
海外基金